title: Prognostic value of trisomy 8 as a single anomaly and the influence of additional cytogenetic aberrations in primary myelodysplastic syndromes.
abstract: Trisomy 8 is the most common chromosomal gain in myelodysplastic syndromes (MDS), however, little is known about the features of MDS with isolated trisomy 8 and the influence of additional cytogenetic aberrations. We determined the characteristics and prognostic factors of 72 patients with trisomy 8 as a single anomaly and analysed also the impact of other aberrations added to trisomy 8 in another 62 patients. According to our study, MDS with isolated trisomy 8 was more frequent in men, with more than one cytopenia in most patients (62%) and having about 4% bone marrow blasts. The multivariate analysis demonstrated that platelet count and percentage bone marrow blasts had the strongest impact on overall survival (OS). The median OS for isolated trisomy 8, trisomy 8 plus one aberration (tr8 + 1), plus two (tr8 + 2) and plus three or more aberrations (tr8 + ≥3) was 34·3, 40, 23·4 and 5·8 months, respectively (P < 0·001). Trisomy 8 confers a poorer prognosis than a normal karyotype in MDS patients with ≥5% bone marrow blasts. This study supports the view that MDS with isolated trisomy 8 should be included in the intermediate cytogenetic risk group.
authors.affiliation: Laboratori de Citologia Hematològica, Laboratori de Citogenètica Molecular, Serveis de Patologia i d'Hematologia Cl\xEDnica, Hospital del Mar, Barcelona, Spain.
authors.forename: Sílvia
authors.initials: S
authors.lastname: Saumell
authors.forename: Lourdes
authors.initials: L
authors.lastname: Florensa
authors.forename: Elisa
authors.initials: E
authors.lastname: Luño
authors.forename: Carmen
authors.initials: C
authors.lastname: Sanzo
authors.forename: Consuelo
authors.initials: C
authors.lastname: Cañizo
authors.forename: Jesus M
authors.initials: JM
authors.lastname: Hernández
authors.forename: José
authors.initials: J
authors.lastname: Cervera
authors.forename: Miguel A
authors.initials: MA
authors.lastname: Gallart
authors.forename: Félix
authors.initials: F
authors.lastname: Carbonell
authors.forename: Rosa
authors.initials: R
authors.lastname: Collado
authors.forename: Leonor
authors.initials: L
authors.lastname: Arenillas
authors.forename: Carme
authors.initials: C
authors.lastname: Pedro
authors.forename: Joan
authors.initials: J
authors.lastname: Bargay
authors.forename: Benet
authors.initials: B
authors.lastname: Nomdedeu
authors.forename: Blanca
authors.initials: B
authors.lastname: Xicoy
authors.forename: Teresa
authors.initials: T
authors.lastname: Vallespí
authors.forename: José M
authors.initials: JM
authors.lastname: Raya
authors.forename: Luis
authors.initials: L
authors.lastname: Belloch
authors.forename: Guillermo F
authors.initials: GF
authors.lastname: Sanz
authors.forename: Francesc
authors.initials: F
authors.lastname: Solé
mesh_terms: D000328:Adult; D000368:Aged; D002869:Chromosome Aberrations; D002898:Chromosomes, Human, Pair 8; D018450:Disease Progression; D005260:Female; D006801:Humans; D059785:Karyotype; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000235:genetics* / Q000401:mortality*; D011379:Prognosis; D012306:Risk; D014314:Trisomy